JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2004; 43:2225-2232, doi:10.1016/j.jacc.2003.11.065
© 2004 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sposito, A. C.
Right arrow Articles by Maranhão, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sposito, A. C.
Right arrow Articles by Maranhão, R. C.

CLINICAL RESEARCH: TRIGLYCERIDES AND RISK

Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment

A long-term follow-up study

Andrei C. Sposito, MD, PhD*, Pedro A. Lemos, MD{dagger}, Raul D. Santos, MD, PhD{dagger}, Whady Hueb, MD, PhD{dagger}, Carmen G. C. Vinagre, PhD{dagger}, Edgard Quintella, MD{dagger}, Otavio Carneiro, MD{dagger}, M. John Chapman, PhD, DSc{ddagger}, Jose A. F. Ramires, MD, PhD, FACC*{dagger} and Raul C. Maranhão, MD, PhD{dagger}§,*

* Heart Institute (InCor), Zerbini Foundation, Brasilia, Brazil
{dagger} Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil
{ddagger} INSERM Unité 551, Hôpital de la Pitié-Salpetriere, Paris, France
§ Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil

Manuscript received January 29, 2003; revised manuscript received November 7, 2003, accepted November 13, 2003.

* Reprint requests and correspondence: Prof. Raul C. Maranhão, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina USP, Av. Dr. Eneas Carvalho Aguiar, 44., 05403.900 São Paulo, SP, Brazil.
ramarans{at}usp.br

OBJECTIVES: We sought to verify whether the intravascular metabolism of chylomicron-like emulsion may predict the clinical evolution of patients with coronary artery disease (CAD) undergoing secondary prevention therapy of CAD.

BACKGROUND: Case-control studies have suggested an association between impaired intravascular catabolism of triglyceride (TG)-rich lipoproteins and CAD. However, evidence is lacking with respect to the potential clinical relevance of this metabolic disorder in CAD patients.

METHODS: During a period of 4.5 ± 0.9 years, we followed up 63 stable CAD patients (mean age 60 ± 10 years) undergoing secondary prevention therapy (low-density lipoprotein cholesterol <100 mg/dl) in whom kinetic studies of the in vivo catabolism of chylomicron-like emulsions were performed. At enrollment into the study, fasting patients were injected intravenously with a chylomicron-like emulsion labeled with radioactive triglyceride (3H-TG) and cholesteryl esters (14C-CE) to evaluate the efficacy of intravascular TG lipolysis.

RESULTS: At baseline, CAD patients displayed a diminished fractional clearance rate (FCR) for 3H-TG (–26%; p = 0.027), for 14C-CE (–37%; p = 0.015), and for delipidation index (DI) (–26%; p = 0.02) as compared with 35 control subjects. During follow-up of secondary prevention therapy, 33% of CAD patients (n = 21) presented with clinically refractory angina and aggravated coronary angiographic severity. The FCR for 3H-TG (–44%; p = 0.005) and DI (–41%; p = 0.006) in those patients with refractory angina was significantly lower than that observed in those with stable evolution. Moreover, in a Cox multivariate regression analysis, the presence of a DI less than the median value was an independent predictor of an unfavorable clinical evolution (adjusted hazard ratio 3.32; 95% confidence interval 1.21 to 9.14; p = 0.020).

CONCLUSIONS: The current study establishes that delayed intravascular TG lipolysis is a strong and independent predictor of evolution to severe angina among patients undergoing secondary prevention therapy of CAD.

Abbreviations and Acronyms
  ACAD = aggravating coronary artery disease
  ACE = angiotensin-converting enzyme
  CAD = coronary artery disease
  CE = cholesterol ester
  CI = confidence interval
  DI = delipidation index
  FCR = fractional clearance rate
  HDL = high-density lipoprotein
  HR = hazard ratio
  LDL = low-density lipoprotein
  LPL = lipoprotein lipase
  SCAD = stable coronary artery disease
  TG = triglyceride
  VLDL = very low-density lipoprotein




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, B. H. Greenberg, J. D. Knoke, K. U. Knowlton, W. Y.W. Lew, J. Narula, D. Sahn, et al.
Highlights of the year in JACC 2004
J. Am. Coll. Cardiol., January 4, 2005; 45(1): 137 - 153.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2004 by the American College of Cardiology Foundation.